[PDF][PDF] VEGF in signaling and disease: beyond discovery and development

RS Apte, DS Chen, N Ferrara - Cell, 2019 - cell.com
The discovery of vascular endothelial-derived growth factor (VEGF) has revolutionized our
understanding of vasculogenesis and angiogenesis during development and physiological …

Overcoming resistance to tumor-targeted and immune-targeted therapies

M Aldea, F Andre, A Marabelle, S Dogan, F Barlesi… - Cancer Discovery, 2021 - AACR
Resistance to anticancer therapies includes primary resistance, usually related to lack of
target dependency or presence of additional targets, and secondary resistance, mostly …

Paralog knockout profiling identifies DUSP4 and DUSP6 as a digenic dependence in MAPK pathway-driven cancers

T Ito, MJ Young, R Li, S Jain, A Wernitznig… - Nature …, 2021 - nature.com
Although single-gene perturbation screens have revealed a number of new targets,
vulnerabilities specific to frequently altered drivers have not been uncovered. An important …

The emerging clinical relevance of genomics in cancer medicine

MF Berger, ER Mardis - Nature reviews Clinical oncology, 2018 - nature.com
The combination of next-generation sequencing and advanced computational data analysis
approaches has revolutionized our understanding of the genomic underpinnings of cancer …

Targeting alterations in the RAF–MEK pathway

R Yaeger, RB Corcoran - Cancer discovery, 2019 - AACR
The MAPK pathway is one of the most commonly mutated oncogenic pathways in cancer.
Although RAS mutations are the most frequent MAPK alterations, less frequent alterations in …

Radiomics: images are more than pictures, they are data

RJ Gillies, PE Kinahan, H Hricak - Radiology, 2016 - pubs.rsna.org
In the past decade, the field of medical image analysis has grown exponentially, with an
increased number of pattern recognition tools and an increase in data set sizes. These …

From melanocytes to melanomas

AH Shain, BC Bastian - nature reviews Cancer, 2016 - nature.com
Melanomas on sun-exposed skin are heterogeneous tumours, which can be subtyped on
the basis of their cumulative levels of exposure to ultraviolet (UV) radiation. A melanocytic …

Ten years of anti-vascular endothelial growth factor therapy

N Ferrara, AP Adamis - Nature reviews Drug discovery, 2016 - nature.com
The targeting of vascular endothelial growth factor A (VEGFA), a crucial regulator of both
normal and pathological angiogenesis, has revealed innovative therapeutic approaches in …

[HTML][HTML] Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

GV Long, D Stroyakovskiy, H Gogas… - … England Journal of …, 2014 - Mass Medical Soc
Background Combined BRAF and MEK inhibition, as compared with BRAF inhibition alone,
delays the emergence of resistance and reduces toxic effects in patients who have …

First-in-class ERK1/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: results of a phase I dose-escalation and expansion study

RJ Sullivan, JR Infante, F Janku, DJL Wong… - Cancer discovery, 2018 - AACR
Abstract Ulixertinib (BVD-523) is an ERK1/2 kinase inhibitor with potent preclinical activity in
BRAF-and RAS-mutant cell lines. In this multicenter phase I trial (NCT01781429), 135 …